Albuferon, an experimental hepatitis C treatment from Human Genome Sciences, is not effective when administered on a monthly basis but is more effective when taken every two weeks in combination with another medication, according to trial data released by the company on Tuesday, the Wall Street Journal reports. About 75% of patients taking a 1,200-microgram dose of Albuferon every two weeks in combination with Ribavirin exhibited lower hepatitis C viral levels, compared with 66% of patients receiving 180 micrograms of Pegasys, a hepatitis C treatment from Roche Holding, every seven days, according to phase III trial data. The trial finds that Albuferon was not as effective as Pegasys when taken at four-week intervals, although it might be more effective if given in higher doses, the Journal reports (Hinton, Wall Street Journal, 3/15). According to the Washington Post, the data "raised questions about whether Albuferon is superior enough to let it compete with entrenched products that doctors are long accustomed to prescribing." Albuferon -- a variation of interferon, which has been on the market for several years -- was developed "to work better than existing forms of the drug while allowing people to inject themselves less often," the Post reports. HGS said it will move forward with larger scale trials to receive FDA approval. HGS CEO H. Thomas Watkins said, "Quite honestly, we like what we see in terms of these interim results" (Gillis, Washington Post, 3/15).

"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Pegasys.